Breakdown | TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 3.79M | 3.43M | 13.37M | 18.17M | 9.03M | 1.93M |
Gross Profit | 1.55M | 1.02M | 5.53M | 5.05M | 4.93M | 1.21M |
EBITDA | -12.77M | -13.33M | -9.59M | -12.68M | -11.68M | -12.25M |
Net Income | -31.28M | -6.99M | -9.95M | -8.38M | -16.03M | -12.76M |
Balance Sheet | ||||||
Total Assets | 13.04M | 12.79M | 13.65M | 22.27M | 14.42M | 11.34M |
Cash, Cash Equivalents and Short-Term Investments | 6.82M | 6.43M | 7.15M | 15.22M | 6.55M | 7.79M |
Total Debt | 472.39K | 739.16K | 1.24M | 0.00 | 0.00 | 2.35M |
Total Liabilities | 2.81M | 3.82M | 8.78M | 9.36M | 3.30M | 5.63M |
Stockholders Equity | 10.22M | 9.14M | 4.95M | 12.91M | 11.11M | 5.72M |
Cash Flow | ||||||
Free Cash Flow | -13.95M | -14.12M | -6.30M | -9.47M | -15.94M | -12.21M |
Operating Cash Flow | -13.25M | -13.71M | -6.22M | -8.98M | -13.39M | -11.14M |
Investing Cash Flow | -695.27K | -407.90K | -1.10M | -489.55K | -2.55M | -1.06M |
Financing Cash Flow | 17.62M | 13.40M | 0.00 | 18.13M | 14.70M | 19.43M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | $16.63M | ― | -25.29% | ― | 26.67% | 44.02% | |
59 Neutral | $11.82M | ― | -126.34% | ― | 3.87% | 91.76% | |
46 Neutral | C$189.62M | -4.26 | -8.56% | 3.09% | 13.57% | -1.98% | |
42 Neutral | $2.45M | ― | -141.39% | ― | -58.46% | 47.98% | |
39 Underperform | $2.25M | ― | -265.37% | ― | -13.05% | 49.76% | |
34 Underperform | $2.55M | ― | -358.41% | ― | ― | 71.89% | |
$4.87M | ― | -24.75% | ― | ― | ― |
On September 30, 2024, Applied DNA Sciences’ stockholders approved a reverse stock split to address non-compliance with Nasdaq’s minimum bid price requirements. Effective March 14, 2025, the 1-for-50 reverse stock split aims to reduce the number of outstanding shares from approximately 55.2 million to 1.1 million, helping the company regain compliance and maintain its Nasdaq listing.